Laboratory Products
Haemoglobinopathy Screening Programmes Offer Flexibility
Jul 12 2010
Sebia introduces two new technologies for newborn screening and adult testing of haemoglobinopathies in clinical diagnostic laboratories. The most common forms of these genetically inherited disorders of red blood cell haemoglobin are Sickle Cell disease and Beta Thalassaemia major. From its leading position in protein electrophoresis technology, Sebia is well equipped to fulfill the growing demand worldwide for national haemoglobinopathy screening programmes.
Sebia offers the broadest choice of multipurpose electrophoresis systems and methods. CAPILLARYS™ 2 Neonat Fast for dry spot, cord blood and packed red cell sampling and CAPILLARYS™ 2 Flex Piercing for whole blood/capped tubes haemoglobin as well as serum and urine testing.
CAPILLARYSTM 2 Flex Piercing offers a comprehensive menu for haemoglobins, protein electrophoresis, immunotyping and CDT (carbohydrate-deficient transferrin). For haemoglobinopathy testing, the new cap-piercing capability streamlines workflow with a high throughput of 37 Hb samples/hour, and maximises biohazard safety. Once primary sample tubes are loaded onto the system, the sample rack is gently inverted to ensure
whole blood samples remain homogeneous and produce accurate results. Positive sample identification ensures full traceability from primary sample tube to final result.
These latest innovations strengthen Sebia’s leadership in the field of electrophoresis technology, and position the company as a key player in haemoglobinopathies diagnosis.
Digital Edition
ILM 49.5 July
July 2024
Chromatography Articles - Understanding PFAS: Analysis and Implications Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers LIMS - Essent...
View all digital editions
Events
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia
Jul 31 2024 Chengdu, China
ACS National Meeting - Fall 2024
Aug 18 2024 Denver, CO, USA
Aug 25 2024 Copenhagen, Denmark